Effect of intralesional diprospan injection combined with esomeprazole acid-suppressive on laryngeal contact granuloma

Abstract

Abstract:

AIM:To investigate the efficacy and security of intralesional compound betamethasone injection combined with esomeprazole acid-suppressive therapy for the treatment of laryngeal contact granuloma. METHODS: Seventy-six patients with laryngeal contact granuloma diagnosed from March 2012 to March 2016 were reviewed. Twenty-seven patients took intralesional compound betamethasone injection combined with esomeprazole acid-suppressive therapy as treatment group,the other 67 patients only received esomeprazole acid-suppressive therapy as control group. Control group was treated with oral esomeprazole, 20 mg per time, twice a day for 1 month, followed by esomeprazole 10 mg per time, each morning for half a month, then followed by esomeprazole 10 mg per time, each 2 days for half a month. Treatment group was treated with oral esomeprazole plus intralesional compound betamethasone injection, 0.3-0.5 mL per time, and one time for each month for less than 3 consecutive months. The clinical data of these patients were analyzed. RESULTS: The cure rate was significantly improved in the treatment group (70.37%,19/27) compared with that in the control group (46.94%, 23/49), and the cure time in the treatment group［(2.62±0.37) months］ was significantly shorter than that in the control group［(5.16±0.85) months］. Meanwhile, in those patients with Farwell III and IV grade lesions, the cure rate in the treatment group (60.00%, 6/10) was also significantly higher than that in the control group (14.29%, 3/21). In both groups, the adverse drug reaction mainly included dyspepsia, gasteremphraxis and hiccough. There were no significant differences (P=0.695) in the rate of adverse drug reaction between treatment group (11.11%) and control group (14.29%). CONCLUSION:Intralesional compound betamethasone injection combined with esomeprazole acid-suppressive therapy can be recommended as a safe and effective alternative therapy for laryngeal contact granuloma, especially for the refractory granuloma.

Key words: esomeprazole, compound betamethasone injection, laryngeal contact granuloma, safety

CLC Number:

R767

FANG Xiaobi, ZHOU Qinshuang, LIAO Zhisu. Effect of intralesional diprospan injection combined with esomeprazole acid-suppressive on laryngeal contact granuloma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 680-683.

References

［1］Wang CP,Ko JY,Wang YH,et al.Vocal process granuloma-A result of long-term observation in 53 patients［J］.Oral Oncol,2009,45(9):821-825.
［2］Hong-gang D，He-juan J，Chun-quan Z，et al. Surgery and proton pump inhibitors for treatment of vocal process granulomas［J］. Eur Arch Otorhinolaryngol，2013，270（11）：2921-2926.
［3］Farwell DG,Belafsky PC,Rees CJ.An endoscopic grading system for vocal process granuloma ［J］. J Laryngol Otol，2008，122（10）：1092-1095.
［4］田师宇，李进让. 抑酸药物治疗喉接触性肉芽肿［J］. 中国耳鼻咽喉头颈外科, 2015, 22（9）：438-441.
［5］Wang CT， Lai MS， Lo WC，et al. Intralesional steroid injection：an alternative treatment option for vocal process granuloma in ten patients［J］. Clin Otolaryngol，2013，38（1）：77-81.
［6］Shoffel-havakuk H，Halperin D，Yosef L，et al. Lesions of the posterior glottis：clinical and pathologic considerations and treatment outcome［J］. J Voice，2014，28（2）：263.
［7］Sun GB，Sun N，Tang HH，et al. Zinc sulfate therapy of vocal process granuloma［J］. Eur Arch Otorhinolaryngol，2012，269（9）：2087-2090.
［8］Yiitalo R，Lindestad PA. A retrospective study of contact granuloma［J］. Laryngoscope, 1999，109（3）：433-436.
［9］Karkos PD，George M，Van der veen J，et al. Vocal process granulomas: asystematic review of treatment［J］. Ann Otol Rhinol Laryngol，2014，123（5）：314-320.
［10］叶成刚，罗宇鸿，李伟利，等. 肉毒素-A在难治性喉接触性肉芽肿的治疗应用［J］. 湖北科技学院学报（医学版），2015，29（1）：46-48.
［11］戴玉洋，赵秀丽. 鼻用糖皮质激素的基因组学研究现状［J］. 中国临床药理学杂志，2016，32（11）：1049-1052.

[1]	XIAO Yue, LI Tangfei, XUE Qianfu. Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
[2]	JIA Boying, ZHOU Shuang, WAN Liyan, ZHOU Ying, CUI Yimin. Drug-induced dysphagia risk in elder people——A pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) database [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1109-1120.
[3]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
[4]	LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong. Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
[5]	BAO Jing, CHEN Xiaowen, XIA Liang, ZHAO Yuchen, XIA Ruixiang, XIA Hailong. Clinical efficacy and safety of ixazomib in the treatment of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 782-786.
[6]	PAN Luping, SHI Wujie, SHEN Zhipeng. Efficacy and safety of etoposide combined with carboplatin in children with recurrent medulloblastoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 189-195.
[7]	SHI Lili, LIU Xingan, SHAN Guoyong. Efficacy and safety of apatinib in the further line treatment for patients with advanced colorectal cancer failed after standard therapy and the preliminary analysis of efficacy predictors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1388-1394.
[8]	YANG Haijing, YU Jicheng, WANG Jingjing, LI Nanyang, WU Jufang, ZHANG Hai, XUE Tao, DAI Weiguo, DING Tianling, CAO Guoying. Risk management of biological agents in phase I clinical trials: Case sharing [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 44-48.
[9]	HUA Xudan, XIE Hongyi, YU Shufang. Analysis of the efficacy, safety and economics of prophylactic antibiotics in high-risk neonates guided by C reaction protein and procalcitonin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 561-566.
[10]	WANG Haili, GONG Tianxiao, ZHOU Shixia, MEI Jiazhuan, ZHANG Zhongmian. Efficacy and safety of third-line treatment with mesylate apatinib in patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 567-572.
[11]	KANG Hui, YONG Xiaolan, HU Tingting, CHU Bixin, WANG Lantian. Pharmacokinetic study and safety assessment of lacosamide tablets in Chinese healthy subjects under fasting condition [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 192-197.
[12]	YANG Ke, LI Junling, DU Bin, TIAN Zhongqiu, JING Xiujuan. Single-arm,one-center, exploratory clinical trial of albumin-bound paclitaxel second and more line therapy for advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1281-1286.
[13]	ZHAO Quanfeng, FU Peishu, MA Huan, ZHAO Suyu, GUO Daihong, TANG Min. Study on liver dysfunction related to voriconazole by automatic surveillance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 43-48.
[14]	PENG Peng, YUAN Wei'an, HU Yihui, TANG Jie, JIANG Jian. Analysis of regulatory issues of adverse events in drug clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 78-82.
[15]	YUAN Dian, YU Guo, WANG Daxin. Advances in effects of tyrosine kinase inhibitors on QT interval and its clinical significance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 825-830.